You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Inducible HMGB1 antagonist for viral-induced acute lung injury.

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NHLBI

    For more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a portable beat-to-beat fetal ECG system

    SBC: AUSCULTECH DX LLC            Topic: NICHD

    Project Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. An immunotherapeutic IgY formulation against norovirus diarrhea

    SBC: SCALED MICROBIOMICS LLC            Topic: NIAID

    Project Summary/Abstract for STTR Phase I Application: An immunotherapeutic IgY formulation against norovirus diarrhea Human norovirus (HuNoV) infects millions of people globally each year, causing diarrheal illness resulting in more than 200,000 deaths annually, particularly in the very young, the very old, and the immunocompromised. There is currently neither an effective vaccine nor effective t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine

    SBC: NeuImmune, Inc.            Topic: NIAID

    ABSTRACTGlobally, more than 71 million people are infected with Hepatitis C virus (HCV), with 1-2 million new infections occurring each year. This major health concern necessitates the development of an effective vaccine. Since HCV rapidly accumulates mutations, vaccines must elicit the production of broadly neutralizing antibodies (bnAbs) in a reproducible fashion. The viral envelope E1E2 glycopr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. 3D microprinting-enabled microinjection needle arrays for enhanced therapeutics delivery into the brain

    SBC: SEETRUE TECHNOLOGY, LLC            Topic: 101

    PROJECT SUMMARY Microinjection technologies underlie many research and clinical applications that require gene and cell delivery, including studies and emerging treatments of neurological conditions (e.g., neurodegenerative diseases, traumatic brain injury, and cancer). Unfortunately, challenges associated with the microinjection tools by which the viral vectors and cells inherent in these applica ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)

    SBC: Rise Therapeutics, LLC            Topic: NIAID

    PROJECT SUMMARY Acute respiratory distress syndrome (ARDS) is a severe life-threatening complication that can be caused by viral infection. The disease is characterized by cytokine-driven hyperinflammation and leukocytes count changes. The innate immune response has been linked to ARDS immunopathogenesis. In this regard, neutrophils have been highlighted as essential effector cells in the developm ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. ErythroMer: Nanoscale BioSynthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    Research Summary/Abstract ErythroMer (EM) is a novel biosynthetic blood substitute developed to address the critically unmet need for emergency transfusion in situations where the use of banked red blood cells (RBCs) are either not available or undesirable. EM is a self-assembled lipid-oligomeric hybrid nanoparticle with a high per particle payload of hemoglobin (Hb) and the allosteric modifier, R ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients

    SBC: EMOCHA MOBILE HEALTH INC.            Topic: NHLBI

    Few interventions have proven to be successful in promoting medication adherence and impacting short- and long-term posttransplant outcomes in adolescent heart transplant (HT) recipients. Improving adherence is a persistent challenge with youth experiencing chronic health conditions, especially among adolescent transplant recipients. Adolescent organ transplant recipients experience unique challen ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT In 2020 malaria caused 241M clinical cases and 627,000 deaths, the greatest numbers of annual deaths since 2012. There were more deaths in Africa from malaria than from COVID-19. There is an urgent unmet medical need for a malaria vaccine that prevents infection and disease in individuals and can be deployed in mass vaccination programs for malaria elimination. The RTS,S malaria vaccine w ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government